Mesenchymal Cell News Volume 5.36 | Sep 17 2013

Aggrecan- and COMP-Loaded Poly(L-Lactic-Co-Glycolic Acid) Nanoparticles Stimulate Chondrogenic Differentiation of Human Mesenchymal Stem Cells
Researchers developed a safe and efficient protein delivery system using encapsulation of proteins into biodegradable poly-(L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs). The PLGA NPs were used to deliver proteins into human mesenchymal stem cells. [Stem Cells Dev] Abstract

Toll-Like Receptor 2/6-Dependent Stimulation of Mesenchymal Stem Cells Promotes Angiogenesis by Paracrine Factors
Insufficient angiogenesis is a limiting factor for engraftment of large-scale tissue transplants. Transplantation or stimulation of local mesenchymal stem cells (MSCs) represents a potential solution to enhance angiogenesis. The authors recently identified angiogenic properties for the Toll-like receptor 2/6 agonist MALP-2 and now investigated if MALP-2 could be used to stimulate MSCs in order to promote angiogenesis in vitro and in vivo. [Eur Cell Mater] Abstract | Full Article

Mesenchymal Stem Cells Inhibit Multiple Myeloma Cells via the Fas-L/Fas Pathway
Researchers used a standard disseminated multiple myeloma (MM) model in mice to identify the in vivo effects of intravenous mesenchymal stem cell (MSC) infusion. In addition, a series of in vitro co-culture assays were performed to explore whether Fas/Fas-L is involved in the inhibitory effects of MSCs on MM cells. [Stem Cell Res Ther] Abstract | Full Article

Chondrogenic Differentiation of ATDC5 and hMSCs Could Be Induced by a Novel Scaffold- Tricalcium Phosphate-Collagen- Hyaluronan without Any Exogenous Growth Factors In Vitro
Researchers tested whether a novel tricalcium phosphate-collagen-hyaluronan scaffold had inherent chondro-inductive capacity for chondrogenesis of both ATDC5 and hMSCs without any exogenous growth factors in vitro. [J Biomed Mater Res A] Abstract

Differentiation of Human Bone Marrow Mesenchymal Stem Cells on Decellularized Extracellular Matrix Materials
Primarily harvested bone marrow mesenchymal stem cells (MSCs) and commercially obtained MSCs were induced into osteoblasts and adipocytes on decellularized dermis and mesothelium materials. The MSCs were able to be induced into chondrocytes in pellet form but not when grown as a monolayer on the materials. [J Biomed Mater Res A] Abstract

Restoration of Angiogenic Capacity of Diabetes-Insulted Mesenchymal Stem Cells by Oxytocin
Scientists studied the effect of streptozotocin-induced diabetes on the bone marrow-mesenchymal stem cell (MSC) function, and examined whether diabetes-impaired MSCs could be rescued by pretreatment with oxytocin. [BMC Cell Biol] Abstract | Full Article

Basic Fibroblast Growth Factor Expression Is Implicated in Mesenchymal Stem Cells Response to Light-Induced Retinal Injury
Neurotrophic factor expression in mesenchymal stem cells was investigated after stimulation by supernatants of homogenized retina from normal and light-injured rats. [Cell Mol Neurobiol] Abstract

Valproic Acid Promotes Neuronal Differentiation by Induction of Neuroprogenitors in Human Bone-Marrow Mesenchymal Stromal Cells
Researchers investigated the effects of a histone deacetylases inhibitor, valproic acid, for the neuronal differentiation of human bone marrow-mesenchymal stromal cells. [Neurosci Lett] Abstract

Nanofiber Orientation and Surface Functionalization Modulate Human Mesenchymal Stem Cell Behavior In Vitro
Scientists investigated the effects of nanofiber orientation and surface functionalization on human mesenchymal stem cell migration and osteogenic differentiation. [Tissue Eng Part A] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease Exclusive Rights to Treat PAD with Placental Cells in the U.S.
Pluristem Therapeutics Inc. announced that the company has completed a major step in its intellectual property strategy: the United States Patent and Trademark Office has granted the Company U.S. Patent 8,529,888. This patent covers methods for the treatment of peripheral artery disease with placental-derived adherent stromal cells. [Pluristem Therapeutics Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Visit our events page to see a complete list of events in the mesenchymal cell community.

PhD Position – Biomaterial Imaging (Uppsala University)

Research Associate – Mechanisms of Cardioprotection (University of Louisville)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Senior Scientist – Characterizing Mesenchymal Cell Activity (Celgene Corporation)

Principal Investigator – Developmental & Stem Cell Biology (SickKids Hospital)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.